Target Name: RBM26
NCBI ID: G64062
Review Report on RBM26 Target / Biomarker Content of Review Report on RBM26 Target / Biomarker
RBM26
Other Name(s): RNA-binding motif protein 26 | Cutaneous T-cell lymphoma tumor antigen se70-2 | PRO1777 | RNA-binding protein 26 (isoform 3) | RNA binding motif protein 26, transcript variant 3 | RP11-255E21.1 | CTCL tumor antigen se70-2 | protein phosphatase 1, regulatory 132 | RBM26 variant 3 | RNA-binding protein 26 | cutaneous T-cell lymphoma tumor antigen se70-2 | acidic rich RS domain containing 2 | ZC3H17 | PPP1R132 | C13orf10 | SE70-2 | RNA binding motif protein 26 | Acidic rich RS domain containing 2 | RBM26_HUMAN | ARRS2

RNA-Binding Motif Protein 26 (RBM26) as A Drug Target and Biomarker

RNA-binding motif protein 26 (RBM26) is a protein that plays a critical role in regulating gene expression and has been linked to various diseases, including cancer. Despite its importance, little is known about this protein, and it has not yet been fully studied. In this article, we will explore the potential implications of RBM26 as a drug target and highlight its potential as a biomarker for various diseases.

The RBM26 protein

RBM26 is a protein that was first identified in the ENCYTOCHUS communis cell line as a potential drug target. It is a 26-kDa protein that contains a N-terminal alpha-helix, a central 尾-sheet, and a C-terminal T- loop. RBM26 is expressed in various tissues, including the brain, heart, and liver, and has been shown to play a role in cell signaling, protein synthesis, and stress response.

One of the most interesting features of RBM26 is its ability to interact with RNA molecules. This interaction is mediated by the protein's N-terminal region, which contains a leucine-rich repeat (LRR) domain. LRR domains are known for their ability to form hydrogen bonds with other RNA molecules, including microRNAs and small interfering RNA (siRNA). This interaction between RBM26 and RNA molecules suggests that it may be a useful target for drugs that can modulate gene expression.

Drug targeting RBM26

The potential drug targeting of RBM26 is an exciting area of 鈥嬧?媟esearch, as it has the potential to treat a wide range of diseases. One of the most promising strategies for targeting RBM26 is the use of small molecules, such as drugs that can modulate its activity by binding to specific residues on the protein. This approach has been used to target various proteins and has the potential to be used to target RBM26 as well.

One of the most promising small molecules that can be used to target RBM26 is a drug called 螖-L-tryptophan (螖-Tp), which is a derivative of the amino acid tryptophan. 螖-Tp has been shown to have potent anti- inflammatory and anti-tumor effects and may be a useful drug for the treatment of various diseases, including cancer.

Another small molecule that may be able to target RBM26 is a drug called 螖-L-isoleucine (螖-I), which is a derivative of the amino acid leucine. 螖-I has been shown to have various physiological effects, including the regulation of gene expression and the modulation of cellular signaling pathways.

Biomarker potential

In addition to its potential as a drug target, RBM26 may also have utility as a biomarker for various diseases. The ability of RBM26 to interact with RNA molecules suggests that it may be a useful marker for diseases that are characterized by abnormal gene expression.

One of the most promising applications of RBM26 as a biomarker is its potential to serve as a marker for cancer. Cancer is characterized by the uncontrolled regulation of gene expression, and RBM26 may be used as a marker for diseases that are characterized by such regulation. For example, RBM26 may be used to assess the effectiveness of anti-cancer drugs by measuring the levels of RBM26 in cancer cells.

RBM26 may also be used as a biomarker for other diseases, such as neurodegenerative disorders. These disorders are characterized by the progressive loss of nerve cells, and RBM26 may be used to assess the effectiveness of potential therapies by measuring the levels of RBM26 in affected cells.

Conclusion

In conclusion, RBM26 is a protein that has the potential to be a drug target and a biomarker for various diseases. Further research is needed to fully understand its role and to develop effective therapies that can modulate its activity.

Protein Name: RNA Binding Motif Protein 26

The "RBM26 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBM26 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1 | RCAN2 | RCAN3 | RCAN3AS | RCBTB1 | RCBTB2 | RCC1 | RCC1L | RCC2 | RCCD1 | RCE1 | RCHY1 | RCL1 | RCN1 | RCN1P2 | RCN2 | RCN3 | RCOR1 | RCOR2 | RCOR3 | RCSD1 | RCVRN | RD3 | RD3L | RDH10 | RDH11 | RDH12 | RDH13 | RDH14 | RDH16 | RDH5 | RDH8 | RDM1 | RDUR | RDX | RDXP2 | Reactive oxygen species (ROS) | REC114 | REC8 | RECK